CAS: 1638338-43-8
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
Navicixizumab REF: TM-T76871CAS: 1638338-43-8 | - - - | To inquire | Fri 11 Oct 24 | |
Navicixizumab REF: 3D-CLA1422CAS: 1638338-43-8 | - - - | To inquire | Mon 21 Oct 24 |
Navicixizumab
CAS:1638338-43-8
Navicixizumab, a bispecific VEGF/DLL4 inhibitor, pairs with Paclitaxel in ovarian and other cancer research.
Color and Shape:
Solid
Ref: TM-T76871
5mg | To inquire |
Estimated delivery in United States, on Friday 11 Oct 2024
Navicixizumab
CAS:1638338-43-8
Bispecific monoclonal antibody targeting the Notch ligand delta-like 4 (DLL4) and VEGF
Ref: 3D-CLA1422
Undefined size | To inquire |
Estimated delivery in United States, on Monday 21 Oct 2024